• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    KalVista Appoints Jeb Ledell as Chief Operating Officer

    BUSINESSWIRE

    KalVista Reports Q2 Results and Provides Operational Update

    BUSINESSWIRE

    KalVista Reports Inducement Grants Under Nasdaq LR 5635(c)(4)

    BUSINESSWIRE

    KalVista Pharma Appoints Laurence Reid to Board of Directors

    BUSINESSWIRE

    KalVista Pharma to Present at Upcoming Investor Conferences

    BUSINESSWIRE

    KalVista Report Inducement Grants Under Nasdaq LR 5635(c)(4)

    BUSINESSWIRE

    KalVista Presents Sebetralstat Data at Allergy Congress 2024

    BUSINESSWIRE

    KalVista Pharmaceuticals To Present At ACAAI Annual Meeting

    BUSINESSWIRE

    KalVista Presents Sebetralstat Data At HAEi Global Forum

    BUSINESSWIRE

    KalVista Pharma Reports Inducement Grants Under Nasdaq LR 5635(c)(4)

    BUSINESSWIRE

    KalVista Submit Additional Marketing Application For Sebetralstat

    BUSINESSWIRE

    KalVista To Present Nine Abstracts At HAEi GAF

    BUSINESSWIRE

    KalVista Appoints Brian Piekos as Chief Financial Officer

    BUSINESSWIRE

    KalVista To Join Cantor Global Healthcare Conference

    BUSINESSWIRE

    KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024

    BUSINESSWIRE

    KalVista Pharmaceuticals Reports Fiscal Q1 Results and Operational Update

    BUSINESSWIRE

    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

    BUSINESSWIRE

    KalVista Announces FDA Acceptance of Sebetralstat for Hereditary Angioedema

    BUSINESSWIRE

    KalVista To Present Six Abstracts At 2024 Bradykinin Symposium

    BUSINESSWIRE

    KalVista’s Sebetralstat Application Validated By European Medicines Agency

    BUSINESSWIRE

    KalVista Pharmaceuticals Reports Inducement Grants

    BUSINESSWIRE

    KalVista Pharmaceuticals Provides Operational And Fiscal Year Update

    BUSINESSWIRE

    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

    BUSINESSWIRE

    KalVista Initiates KONFIDENT-KID Trial for Treatment Hereditary Angioedema

    BUSINESSWIRE

    KalVista Submits NDA To FDA For Sebetralstat as Oral Treatment Angioedema

    BUSINESSWIRE

    KalVista files first oral on-demand HAE drug with FDA

    PHARMAPHORUM

    KalVista Presents Data At Allergy, Dermatology Conferences

    BUSINESSWIRE

    KalVista: Reports Nasdaq Inducement Grants

    BUSINESSWIRE

    KalVista Presents Unmet Needs Data In Hereditary Angioedema At EAACI

    BUSINESSWIRE

    KalVista Oral Sebetralstat Phase 3 Data In NEJM For Hereditary Angioedema

    BUSINESSWIRE

    Kalvista Eaaci 2024 Abstracts: Ten Presentations At Allergy Congress

    BUSINESSWIRE

    KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

    BUSINESSWIRE

    KalVista Reports Nasdaq Listing Rule Inducement Grants

    BUSINESSWIRE

    KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year

    BUSINESSWIRE

    KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

    BUSINESSWIRE

    KalVista to Present at 23rd Annual Needham Virtual Healthcare Conference

    BUSINESSWIRE

    KalVista Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    KalVista Presents Data on Burden of Treatment and HAE Attack Journey

    BUSINESSWIRE

    KalVista Awarded UK PIM Designation for Sebetralstat

    BUSINESSWIRE

    KalVista Pharmaceuticals Reports Third Fiscal Quarter Results

    BUSINESSWIRE

    KalVista Pharmaceuticals to Present HAE Attack Journey Data

    BUSINESSWIRE

    KalVista Announces Appointment of Benjamin L. Palleiko as CEO

    BUSINESSWIRE

    KalVista to Participate in the Leerink Partners 2024 Biopharma Conference

    BUSINESSWIRE

    KalVista Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    KalVista Presents Data on Unmet Needs in HAE from a Patient Perspective

    BUSINESSWIRE

    KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data

    BUSINESSWIRE

    KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat

    BUSINESSWIRE

    This Insider Has Just Sold Shares In KalVista Pharmaceuticals

    SIMPLYWALL

    KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data

    BUSINESSWIRE

    KalVista Announces Pricing of a $160.1M Public Offering of Common Stock

    PRESS RELEASE

    KalVista Announces Proposed Public Offering of Common Stock

    BUSINESSWIRE

    KalVista reports PhIII success of angioedema drug

    ENDPTS

    KalVista Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    KalVista Announces Publication of First Oral Factor XIIa Data in Pharmacology

    BUSINESSWIRE

    KalVista Pharmaceuticals Reports Second Fiscal Quarter Results

    BUSINESSWIRE

    KalVista Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    KalVista Presents Real-World Data at the 2023 Annual Scientific Meeting

    BUSINESSWIRE

    KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved

    BUSINESSWIRE

    KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

    BUSINESSWIRE

    KalVista Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.